Skye Bioscience Inc (SKYE)

[Closewatcher]

NB1111 is still very much a lead candidate or dual-lead.

November 15 Press Release:

"NB1111 has performed above expectations in the ability to lower IOP in these animal models. We want to further explore the neuroprotective effects of cannabinoids upon the optic nerve and move the ophthalmology program into human testing. I am also happy to report that our colleagues at the University of Mississippi have been able to develop an early ocular formulation of our CBD analogue, and in doing so, expands our ocular program into a full-fledged ophthalmology platform that could address multiple eye diseases beyond glaucoma, including diseases of the retina," noted Brian Murphy, MD, MBA, Nemus CEO and Chief Medical Officer.

March 15th, 2017

03/20/17 -- NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma. The aim of the agreement is to conduct initial studies assessing the preparation of clinical-grade eye drops using the patented Molecular Envelope Technology (MET) developed by Nanomerics. Work under the agreement will commence on a future date to be determined by Nemus in connection with its development plans and corporate objectives.